Gene info: ID 2213

Gene: FCGR2B

GENE ID: 2213

Synonyms: CD32|CD32B|FCG2|FCGR2|IGFR2

Description: Fc fragment of IgG receptor IIb

Gene type: protein-coding

Location: 1q23.3

dbXrefs: Ensembl:ENSG00000072694 MIM:604590 Vega:OTTHUMG00000034470 UniprotKB:P31994

RefSeq: NG_023318.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 1

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 3.932e-1 (AD) 6.127e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
LILRB5	0.827
CPED1	0.775
F13A1	0.767
MARCO	0.766
KCNMB1	0.713
TRABD2B	0.709
GATA6	0.699
OR51E1	0.697
FBLN5	0.697
KCNE3	0.693

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
HES6	-0.315
WIF1	-0.291
BAIAP2L2	-0.29
KREMEN2	-0.281
HAGHL	-0.28
TEX29	-0.279
SLC7A10	-0.276
CCDC78	-0.264
SOHLH1	-0.263
MOXD1	-0.262

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00002	Cetuximab	BiotechDrug	205923-56-4	Approved	Target
DB00005	Etanercept	BiotechDrug	185243-69-0	Approved\|Investigational	Target
DB00028	Immune Globulin Human	BiotechDrug	9007-83-4	Approved\|Investigational	Target
DB00051	Adalimumab	BiotechDrug	331731-18-1	Approved	Target
DB00054	Abciximab	BiotechDrug	143653-53-6	Approved	Target
DB00056	Gemtuzumab ozogamicin	BiotechDrug	220578-59-6	Approved\|Investigational	Target
DB00072	Trastuzumab	BiotechDrug	180288-69-1	Approved\|Investigational	Target
DB00073	Rituximab	BiotechDrug	174722-31-7	Approved	Target
DB00074	Basiliximab	BiotechDrug	179045-86-4	Approved\|Investigational	Target
DB00075	Muromonab	BiotechDrug	140608-64-6	Approved\|Investigational	Target
DB00078	Ibritumomab tiuxetan	BiotechDrug	206181-63-7	Approved\|Investigational	Target
DB00081	Tositumomab	BiotechDrug	208921-02-2	Approved\|Investigational	Target
DB00087	Alemtuzumab	BiotechDrug	216503-57-0	Approved\|Investigational	Target
DB00092	Alefacept	BiotechDrug	222535-22-0	Approved\|Investigational\|Withdrawn	Target
DB00095	Efalizumab	BiotechDrug	214745-43-4	Approved\|Investigational	Target
DB00098	Antithymocyte immunoglobulin (rabbit)	BiotechDrug		Approved	Target
DB00108	Natalizumab	BiotechDrug	189261-10-7	Approved\|Investigational	Target
DB00110	Palivizumab	BiotechDrug	188039-54-5	Approved\|Investigational	Target
DB00111	Daclizumab	BiotechDrug	152923-56-3	Investigational\|Withdrawn	Target
DB00112	Bevacizumab	BiotechDrug	216974-75-3	Approved\|Investigational	Target
DB11767	Sarilumab	BiotechDrug	1189541-98-7	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C049325	1,2-dithiol-3-thione	"1,2-dithiol-3-thione results in decreased expression of FCGR2B mRNA"	19162173
C404910	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane	"2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the expression of FCGR2B mRNA"	19414516
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	"2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of FCGR2B mRNA"	23146750
C023514	2,6-dinitrotoluene	"2,6-dinitrotoluene affects the expression of FCGR2B mRNA"	21346803
C009505	4,4'-diaminodiphenylmethane	"4,4'-diaminodiphenylmethane results in increased expression of FCGR2B mRNA"	18648102
C027576	4-hydroxy-2-nonenal	4-hydroxy-2-nonenal results in decreased expression of FCGR2B mRNA	19191707
D000082	Acetaminophen	Acetaminophen affects the expression of FCGR2B mRNA	17562736
C033968	alizapride	alizapride results in decreased expression of FCGR2B protein	10075867
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of FCGR2B mRNA	16483693
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of FCGR2B mRNA	24449571
D001564	Benzo(a)pyrene	AHR protein affects the reaction [Benzo(a)pyrene affects the expression of FCGR2B mRNA]	22228805
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of FCGR2B mRNA	19770486
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of FCGR2B mRNA	22228805
D004958	Estradiol	Estradiol results in increased expression of FCGR2B mRNA	19484750
C095105	bexarotene	[bexarotene co-treated with Tamoxifen] results in decreased expression of FCGR2B mRNA	17630414
C452139	BIRB 796	BIRB 796 results in decreased expression of FCGR2B mRNA	21328587
C006780	bisphenol A	bisphenol A results in increased expression of FCGR2B mRNA	24586524
C006780	bisphenol A	bisphenol A results in increased expression of FCGR2B mRNA	25181051
D002104	Cadmium	Cadmium results in decreased expression of FCGR2B mRNA	24376830
D002235	Carbofuran	Carbofuran results in increased expression of FCGR2B mRNA	20211217
D002251	Carbon Tetrachloride	Carbon Tetrachloride affects the expression of FCGR2B mRNA	12734012
C010063	carbonyl sulfide	carbonyl sulfide results in increased expression of FCGR2B mRNA	19395590
D002509	Cephaloridine	Cephaloridine results in increased expression of FCGR2B mRNA	18500788
D002746	Chlorpromazine	Chlorpromazine results in decreased expression of FCGR2B protein	10075867
C418118	CI 1044	CI 1044 results in increased expression of FCGR2B mRNA	17569694
C012843	cinnamic aldehyde	cinnamic aldehyde results in increased expression of FCGR2B mRNA	19524605
D020117	Cisapride	Cisapride results in decreased expression of FCGR2B protein	10075867
D002995	Clofibric Acid	[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of FCGR2B mRNA	17602206
D003042	Cocaine	Cocaine results in decreased expression of FCGR2B mRNA	27899881
D003078	Colchicine	Colchicine results in increased expression of FCGR2B mRNA	20624997
D003471	Cuprizone	Cuprizone results in increased expression of FCGR2B mRNA	27523638
D003907	Dexamethasone	Dexamethasone results in increased expression of FCGR2B mRNA	21041162
D004041	Dietary Fats	Dietary Fats results in decreased expression of FCGR2B mRNA	18042831
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate affects the expression of FCGR2B mRNA	27405655
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of FCGR2B mRNA	19850644
D004051	Diethylhexyl Phthalate	PPARA protein promotes the reaction [Diethylhexyl Phthalate results in decreased expression of FCGR2B mRNA]	19850644
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of FCGR2B mRNA	17602206
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of FCGR2B mRNA	21041162
D004317	Doxorubicin	[[MT1 protein co-treated with MT2 protein] affects the susceptibility to Doxorubicin] which affects the expression of FCGR2B mRNA	21040762
D004317	Doxorubicin	Doxorubicin results in increased expression of FCGR2B mRNA	20211217
D000431	Ethanol	Ethanol affects the expression of FCGR2B mRNA	26730594
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of FCGR2B mRNA	15834898\|1735126
D005054	Eugenol	Eugenol results in increased expression of FCGR2B mRNA	17374397
C082360	fipronil	fipronil results in increased expression of FCGR2B mRNA	23962444
D005557	Formaldehyde	Formaldehyde results in increased expression of FCGR2B mRNA	24304932
D005839	Gentamicins	Gentamicins results in increased expression of FCGR2B mRNA	22061828
D005897	Glafenine	Glafenine results in increased expression of FCGR2B mRNA	24136188
D017313	Fenretinide	Fenretinide results in decreased expression of FCGR2B mRNA	28973697
C051890	irinotecan	irinotecan results in increased expression of FCGR2B mRNA	20097248
D007545	Isoproterenol	Isoproterenol results in increased expression of FCGR2B mRNA	20003209
D007545	Isoproterenol	Isoproterenol results in increased expression of FCGR2B mRNA	20211217
C098607	JP8 aviation fuel	JP8 aviation fuel results in increased expression of FCGR2B protein	17337753
C561695	(+)-JQ1 compound	(+)-JQ1 compound inhibits the reaction [[SP11 protein co-treated with FLI1 protein co-treated with ERG protein co-treated with CEBPB protein co-treated with MYB protein co-treated with BRD4 protein] binds to FCGR2B enhancer]	25982114
C561695	(+)-JQ1 compound	(+)-JQ1 compound inhibits the reaction [[SP11 protein co-treated with FLI1 protein co-treated with ERG protein co-treated with CEBPB protein co-treated with MYB protein co-treated with BRD4 protein] binds to FCGR2B promoter]	25982114
C561695	(+)-JQ1 compound	(+)-JQ1 compound inhibits the reaction [[SP11 protein co-treated with FLI1 protein co-treated with ERG protein co-treated with CEBPB protein co-treated with MYB protein] results in increased expression of FCGR2B mRNA]	25982114
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of FCGR2B mRNA	25982114
D048628	Ketolides	Ketolides analog results in decreased expression of FCGR2B mRNA	24967691
D016729	Leuprolide	Leuprolide results in increased expression of FCGR2B protein	10075867
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of FCGR2B mRNA	21461237
D008070	Lipopolysaccharides	Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of FCGR2B mRNA]	21461237
D008550	Melatonin	Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of FCGR2B mRNA]	21461237
D008550	Melatonin	Melatonin results in decreased expression of FCGR2B mRNA	21461237
D008627	Mercuric Chloride	FCGR2B protein affects the susceptibility to Mercuric Chloride	18314309
D008727	Methotrexate	Methotrexate results in decreased expression of FCGR2B mRNA	17400583
D008767	Methylmercury Compounds	Methylmercury Compounds results in increased expression of FCGR2B mRNA	21628967
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of FCGR2B mRNA	23649840
D008774	Methylphenidate	Methylphenidate results in increased expression of FCGR2B mRNA	22470460
D008787	Metoclopramide	Metoclopramide results in decreased expression of FCGR2B protein	10075867
C523799	MRK 003	FCGR2B results in increased susceptibility to MRK 003	19903844
D009151	Mustard Gas	Mustard Gas results in increased expression of FCGR2B mRNA	15674843\|1895507
D037742	Nanotubes, Carbon	"Nanotubes, Carbon affects the expression of FCGR2B mRNA"	23845593
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in increased expression of FCGR2B mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of FCGR2B mRNA"	25554681
D009532	Nickel	Nickel results in increased expression of FCGR2B mRNA	24768652\|2558310
C029938	nickel sulfate	nickel sulfate results in increased expression of FCGR2B mRNA	17374397
D026423	S-Nitroso-N-Acetylpenicillamine	S-Nitroso-N-Acetylpenicillamine results in decreased expression of FCGR2B mRNA	12102619
D010081	Oxazolone	Oxazolone results in increased expression of FCGR2B mRNA	17374397
D017239	Paclitaxel	Paclitaxel results in increased expression of FCGR2B mRNA	18754875
D000073878	Palm Oil	Palm Oil results in decreased expression of FCGR2B mRNA	18042831
D010426	Pentosan Sulfuric Polyester	Pentosan Sulfuric Polyester results in increased expression of FCGR2B mRNA	28973697
D010479	Pergolide	Pergolide results in increased expression of FCGR2B protein	10075867
D010615	Phenacetin	Phenacetin results in increased expression of FCGR2B mRNA	17082564
C030299	phenylhydrazine	phenylhydrazine results in increased expression of FCGR2B mRNA	17082564
C006253	pirinixic acid	pirinixic acid results in decreased expression of FCGR2B mRNA	18445702\|2005976
C006253	pirinixic acid	PPARA protein promotes the reaction [pirinixic acid results in decreased expression of FCGR2B mRNA]	20059764
C060540	polyhexamethyleneguanidine	polyhexamethyleneguanidine results in increased expression of FCGR2B mRNA	27989595
D011441	Propylthiouracil	Propylthiouracil results in increased expression of FCGR2B mRNA	24780913
C010313	pseudocumene	pseudocumene results in increased expression of FCGR2B protein	17337753
D011791	Quartz	Quartz results in increased expression of FCGR2B mRNA	19836432
D011794	Quercetin	Quercetin results in increased expression of FCGR2B mRNA	15309432
C534628	SCH 23390	SCH 23390 results in decreased expression of FCGR2B protein	10075867
D012822	Silicon Dioxide	Silicon Dioxide analog results in decreased expression of FCGR2B mRNA	25895662
D012822	Silicon Dioxide	Silicon Dioxide results in increased expression of FCGR2B mRNA	22431001
D012999	Soman	Soman results in increased expression of FCGR2B mRNA	19281266
D053260	Soot	Soot results in increased expression of FCGR2B mRNA	22461453\|2655175
D013469	Sulpiride	Sulpiride results in decreased expression of FCGR2B protein	10075867
D013605	T-2 Toxin	T-2 Toxin results in increased expression of FCGR2B mRNA	26141394
C061133	tamibarotene	tamibarotene affects the expression of FCGR2B mRNA	15498508
D013629	Tamoxifen	[bexarotene co-treated with Tamoxifen] results in decreased expression of FCGR2B mRNA	17630414
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of FCGR2B mRNA	21041162
C009495	titanium dioxide	titanium dioxide results in increased expression of FCGR2B mRNA	19464567\|2355797
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of FCGR2B mRNA	20133372
D014212	Tretinoin	Tretinoin affects the expression of FCGR2B mRNA	15498508
D014212	Tretinoin	Tretinoin results in increased expression of FCGR2B mRNA	15894607
C015559	trimellitic anhydride	trimellitic anhydride results in increased expression of FCGR2B mRNA	19042947
D014302	Trinitrobenzenesulfonic Acid	Trinitrobenzenesulfonic Acid results in increased expression of FCGR2B mRNA	19524605
C057693	troglitazone	troglitazone results in increased expression of FCGR2B mRNA	28973697
C022884	undecane	undecane results in increased expression of FCGR2B protein	17337753
D014635	Valproic Acid	Valproic Acid results in decreased methylation of FCGR2B gene	29154799
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of FCGR2B gene	25560391
C027429	veralipride	veralipride results in decreased expression of FCGR2B protein	10075867
D014747	Vinblastine	Vinblastine results in increased expression of FCGR2B mRNA	20624997
C025643	vinclozolin	vinclozolin results in increased expression of FCGR2B mRNA	23034163
D014750	Vincristine	Vincristine results in increased expression of FCGR2B mRNA	20624997
C029297	vinylidene chloride	vinylidene chloride results in increased expression of FCGR2B mRNA	26682919
D024483	Vitamin K 3	Vitamin K 3 affects the expression of FCGR2B mRNA	20829426

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001540	amyloid-beta binding	-	IPI	23921129
GO:0005515	protein binding	-	IPI	8577729 9148918 9603468 10382761 11567028 17474147 24642916
GO:0019772	low-affinity IgG receptor activity	-	IDA	2142460
GO:0019864	IgG binding	-	IDA	2142460
GO:0044877	protein-containing complex binding	-	IPI	23921129

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001811	negative regulation of type I hypersensitivity	-	ISS	26683154
GO:0001814	negative regulation of antibody-dependent cellular cytotoxicity	-	TAS	26683154
GO:0002266	follicular dendritic cell activation	-	TAS	26683154
GO:0002313	mature B cell differentiation involved in immune response	-	TAS	26683154
GO:0002316	follicular B cell differentiation	-	TAS	26683154
GO:0002436	immune complex clearance by monocytes and macrophages	-	TAS	26683154
GO:0002605	negative regulation of dendritic cell antigen processing and presentation	-	TAS	26683154
GO:0002622	regulation of B cell antigen processing and presentation	-	TAS	26683154
GO:0002638	negative regulation of immunoglobulin production	-	ISS	26683154
GO:0002819	regulation of adaptive immune response	-	TAS	26683154
GO:0002865	negative regulation of acute inflammatory response to antigenic stimulus	-	ISS	26683154
GO:0002922	positive regulation of humoral immune response	-	TAS	26683154
GO:0002924	negative regulation of humoral immune response mediated by circulating immunoglobulin	-	ISS	26683154
GO:0006898	receptor-mediated endocytosis	-	IDA	2142460
GO:0006911	phagocytosis, engulfment	-	ISS	26683154
GO:0006952	defense response	-	ISS	26683154
GO:0006954	inflammatory response	-	TAS	26683154
GO:0006955	immune response	-	TAS	2142460
GO:0007165	signal transduction	-	TAS	2142460
GO:0009617	response to bacterium	-	ISS	26683154
GO:0010469	regulation of signaling receptor activity	-	TAS	26683154
GO:0016032	viral process	-	IEA	-
GO:0016064	immunoglobulin mediated immune response	-	ISS	26683154
GO:0019886	antigen processing and presentation of exogenous peptide antigen via MHC class II	-	ISS	26683154
GO:0021549	cerebellum development	-	ISS	26683154
GO:0030889	negative regulation of B cell proliferation	-	ISS	26683154
GO:0032693	negative regulation of interleukin-10 production	-	ISS	26683154
GO:0038096	Fc-gamma receptor signaling pathway involved in phagocytosis	-	IDA	2142460
GO:0043031	negative regulation of macrophage activation	-	TAS	26683154
GO:0043318	negative regulation of cytotoxic T cell degranulation	-	TAS	26683154
GO:0045088	regulation of innate immune response	-	TAS	26683154
GO:0045576	mast cell activation	NOT	ISS	26683154
GO:0046330	positive regulation of JNK cascade	-	ISS	23921129
GO:0050710	negative regulation of cytokine secretion	-	TAS	26683154
GO:0050765	negative regulation of phagocytosis	-	TAS	26683154
GO:0050766	positive regulation of phagocytosis	-	ISS	26683154
GO:0050776	regulation of immune response	-	TAS	-
GO:0050777	negative regulation of immune response	-	ISS	26683154
GO:0050869	negative regulation of B cell activation	-	TAS	26683154
GO:0071219	cellular response to molecule of bacterial origin	-	ISS	26683154
GO:0090264	regulation of immune complex clearance by monocytes and macrophages	-	TAS	26683154
GO:1901216	positive regulation of neuron death	-	ISS	23921129
GO:1902564	negative regulation of neutrophil activation	-	TAS	26683154
GO:1902950	regulation of dendritic spine maintenance	-	IGI	23921129
GO:1904646	cellular response to amyloid-beta	-	ISS	23921129
GO:1905898	positive regulation of response to endoplasmic reticulum stress	-	ISS	23921129
GO:2001199	negative regulation of dendritic cell differentiation	-	TAS	26683154

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005886	plasma membrane	-	IDA	2142460
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IDA	23921129
GO:0009897	external side of plasma membrane	-	ISS	26683154
GO:0043197	dendritic spine	-	ISS	26683154
GO:0044297	cell body	-	ISS	26683154

KEGG ID	KEGG Term
hsa04145	Phagosome
hsa04380	Osteoclast differentiation
hsa04662	B cell receptor signaling pathway
hsa04666	Fc gamma R-mediated phagocytosis
hsa05150	Staphylococcus aureus infection
hsa05322	Systemic lupus erythematosus

Reactome ID	Reactome Term	Evidence
R-HSA-1280218	Adaptive Immune System	TAS
R-HSA-168256	Immune System	TAS
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
29744169	Inflammatory mediator polymorphisms associate with initial periodontitis in adolescents. (2016 Dec)	Heikkinen AM	Clin Exp Dent Res